Ipc project: C471 Subclass/group: A61K 47/00 Date: 10/10/2014




Yüklə 66.2 Kb.
tarix23.04.2016
ölçüsü66.2 Kb.

IPC project:C471 Subclass/group:A61K 47/00

Date: 10/10/2014



UK Rapporteur proposal




Yellow – add to scheme

Red – remove from scheme

Pink – term to be defined in definition


M

47/00




Medicinal preparations characterised by the non-active ingredients used, e.g., carriers, inert additives; targeting or modifying agents chemically bound to the active ingredient

U

47/02



Inorganic compounds

U

47/04

・・

non metals; compounds thereof

M

47/06



Organic compounds, e.g., ethers, amides, ascorbic acid, cellulose mineral oil, petrolatum

M

47/08

・・

containing oxygen, e.g., ethers, acetals, ketones, quinones, aldehydes, peroxides

M

47/10

・・・

Alcohols; Phenols; Salts thereof, e.g., glycerol; Polyethylene glycol ( PEG); Poloxamers; PEG/POE alkyl ethers ( sugar alcohols A61K 47/26; copolymers containing polyalkylene glycol or poloxamer A61K 47/34 )

U

47/12

・・・

Carboxylic acids; Salts or anhydrides thereof

M

47/14

・・・

Esters of carboxylic acids e.g., fatty acid monoglycerides, medium-chaintriglycerides, parabens

M

47/16

・・

containing nitrogen, e.g., nitro-, nitroso-, azo-compounds, nitriles, cyanates

M

47/18

・・・

Amines ; Quaternary ammonium compounds, e.g., amides, ureas; Oligopeptides having up to 5 amino acids

M

47/20

・・

containing sulfur, e.g., DMSO, docusate, sodium lauryl sulfate (A61K 47/18 takes precedence)

U

47/22

・・

Heterocyclic compounds, e.g., ascorbic acid, tocopherol, pyrrolidones (A61K 47/18 takes precedence)

U

47/24

・・

containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g., cyclomethicone, phospholipids

U

47/26

・・

Carbohydrates, e.g., mono-, di-, oligosaccharides, nucleic acids, sugar alcohols, amino sugars; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters, glycyrrhizin (A61K 47/18 takes precedence)

U

47/28

・・

Steroids, e.g., cholesterol, bile acids, glycyrrhetinic acid (A61K 47/18 takes precedence)

U

47/30

. .

Macromolecular compounds

U

47/32

・・

Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g., carbomers, poly(meth)acrylates, polyvinyl pyrrolidone

U

47/34

・・

Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g., polyesters, polyamino acids, polysiloxanes, copolymers of polyalkylene glycol or poloxamer ( PEG or poloxamers A61K 47/10 )

U

47/36

・・

Polysaccharides ; Derivatives thereof, e.g., gums, starch, alginate, dextrin,hyaluronic acid, chitosan, inulin, agar, pectin

U

47/38

・・・

Cellulose; Derivatives thereof

U

47/40

・・・

Cyclodextrins ; Derivatives thereof (cyclodextrin inclusion compounds A61K 47/48769 )


U

47/42

・・

Proteins ; Polypeptides ; Degradation products thereof ; Derivatives thereof e.g., albumin, gelatin, zein (oligopeptides having up to 5 amino acids A61K 47/18 ; polyamino acids A61K 47/34 )

U

47/44



Natural or modified natural oils, fats or waxes, e.g., (polyethoxylated) castor oil, montan wax, ozokerite, lignite, shellac, rosin, beeswax, lanolin ( synthetic glycerides, e.g., medium-chain triglycerides A61K 47/14 )

U

47/46



Ingredients of undetermined constitution or reaction products thereof, e.g., skin, bone, milk, cotton fiber, eggshell, oxgall, plant extracts

M

47/48



The non-active ingredient being chemically bound to the active ingredient, e.g., polymer-drug conjugates

N

47/48007

・・

the non-active ingredient being a modifying agent

N

47/48015

・・・

the modifying agent being an inorganic compound; e.g., an inorganic ion that is complexed with the active ingredient

N

47/48023

・・・

the modifying agent being an organic compound

N

47/481

・・・・

the modifying agent being also a pharmacologically or therapeutically active agent, i.e., the entire conjugate being a codrug, i.e., a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds, e.g., a polymer of asprin

N

47/48169

・・・

the modifying agent being an organic macromolecular compound, i.e., an oligomeric, polymeric, dendrimeric molecule

N

47/48176

・・・・

the organic macromolecular compound has been obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g., poly(meth)acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol, polystyrene sulfonic acid resin

N

47/48192

・・・・

the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes

N

47/48215

・・・・・

the organic macromolecular compound being a polyoxyalkylene oligomer,polymer, dendrimer, e.g., PEG, PPG, PEO, polyglycerol

N

47/4823

・・・・

the organic macromolecular compound being a polysaccharide or a derivative, e.g., starch, chitosan, chitin, cellulose, pectin, cyclodextrin with the pharmacologically active agent being covalently linked to the external surface of the ring structure, a bacterial polysaccharide or oligosaccharide antigen, a glycosaminoglycan

N

47/48238

・・・

the modifying agent being a protein, peptide, polyamino acid

N

47/48246

・・・・

drug-peptide, protein or polyamino acid conjugates, i.e., the modifying agent being a protein, peptide or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K 47/48338)

N

47/48338

・・・・

peptidic linker, binder, spacer, e.g., peptidic enzyme-labile linker

N

47/48346

・・・・

the modifying agent being a pre-targeting system involving a peptide or protein ( not an antibody A61K 47/48369 ) for targeting specific cells

N

47/48369

・・・

the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g., a Fc-fragment

N

47/48555

・・・

the modifying agent also being a therapeutically active agent, i.e., the entire conjugate is a codrug, i.e., a dimer, oligomer or polymer of a therapeutically active compound, e.g., a polymer of aspirin

N

47/48769

・・

the conjugate being characterized by a special physical or galenical form, e.g., cell, gel, colloid, dispersion, emulsion, particle, capsule, inclusion complex, device or kit




Intellectual Property Office is an operating name of the Patent Office






Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©azrefs.org 2016
rəhbərliyinə müraciət

    Ana səhifə